相关实验视频

Updated: Jul 4, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

针对SARS-CoV-2的治疗抗体和替代形式

Rahel R Winiger¹, Laurent Perez¹

¹University of Lausanne (UNIL), Lausanne University Hospital (CHUV), Service of Immunology and Allergy, and Center for Human Immunology Lausanne (CHIL), Switzerland.

Antiviral research

|February 2, 2024

概括

尽管有疫苗,但COVID-19大流行仍在继续,因为像Omicron这样的SARS-CoV-2变种出现了. 新的抗体疗法至关重要,因为针对尖端蛋白的现有治疗方法已经过时,需要新的治疗策略来为未来的流行病做好准备.

科学领域:

病毒学病毒学
免疫学免疫学免疫学
治疗方法治疗方法

背景情况:

由SARS-CoV-2引起的COVID-19大流行,已成为全球健康的重大挑战.
疫苗和治疗方法的快速发展发生了,但病毒仍在继续演变.
SARS-CoV-2 变种的出现,特别是 Omicron 亚系,使一些现有的抗体治疗变得无效.

研究的目的:

审查目前针对SARS-CoV-2的抗体目标.
提供针对COVID-19治疗进展的概述.
讨论新型抗体格式和为流行病准备所吸取的经验教训.

主要方法:

科学出版物的文献评论. 科学出版物的文献评论.
对抗体点和治疗策略的分析.
评估新兴抗体格式及其潜力.

主要成果:

在SARS-CoV-2尖端蛋白上识别关键抗体标.
目前抗体疗法的疗效和局限性的概述.
探索新的治疗形式,包括多特异性抗体和抗体碎片.
对因病毒进化导致抗体过时的因素的分析.

结论:

随着SARS-CoV-2的不断演变,需要持续开发有效的抗体疗法.
新型抗体格式在克服病毒逃生机制方面表现有前途.
从COVID-19抗体疗法中吸取的经验教训对于提高未来的流行病准备能力至关重要.

关键词:

抗体是对抗体的一种.纳米体是一种纳米体.在RBD中,RBD是RBD.这就是SARS-CoV-2病毒.斯派克斯派克斯派克斯就是一个尖刺.病毒中和是病毒中和.

更多相关视频

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Cross-reactivity

Cross-reactivity